BidaskClub Downgrades Marinus Pharmaceuticals (MRNS) to Hold

BidaskClub cut shares of Marinus Pharmaceuticals (NASDAQ:MRNS) from a buy rating to a hold rating in a research report released on Tuesday morning.

MRNS has been the subject of a number of other research reports. Laidlaw began coverage on Marinus Pharmaceuticals in a research report on Thursday, December 14th. They issued a buy rating and a $18.00 price objective for the company. ValuEngine lowered Marinus Pharmaceuticals from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, JMP Securities restated an outperform rating and issued a $11.00 target price (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 12th.

Marinus Pharmaceuticals (NASDAQ:MRNS) traded down $0.23 during trading on Tuesday, hitting $7.34. The stock had a trading volume of 615,572 shares, compared to its average volume of 1,730,000. The firm has a market cap of $296.76, a PE ratio of -7.89 and a beta of 2.44. Marinus Pharmaceuticals has a 52-week low of $1.06 and a 52-week high of $9.87.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.02.

In related news, major shareholder Bain Capital Life Sciences Inv sold 1,272,547 shares of the firm’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $7.88, for a total value of $10,027,670.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 6.40% of the company’s stock.

A number of hedge funds have recently modified their holdings of MRNS. Bank of New York Mellon Corp purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth $128,000. Citadel Advisors LLC raised its stake in Marinus Pharmaceuticals by 327.8% in the 3rd quarter. Citadel Advisors LLC now owns 51,383 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 39,371 shares during the last quarter. Susquehanna International Group LLP purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth $503,000. EAM Investors LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth $554,000. Finally, Iguana Healthcare Management LLC purchased a new position in Marinus Pharmaceuticals in the 3rd quarter worth $1,027,000. Institutional investors own 49.77% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.

Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit